Mahacort DZ Suspension contains Deflazacort, a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, formulated at a concentration of 6 mg per 5 ml. It is indicated for the management of various inflammatory and autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, allergic disorders, and certain dermatological diseases. Deflazacort exerts its therapeutic effects by modulating the immune response and reducing the production of inflammatory mediators, thereby alleviating symptoms such as swelling, redness, and pain. The suspension form facilitates ease of administration, particularly in pediatric and geriatric populations or patients with difficulty swallowing tablets. Mahacort DZ Suspension should be used under strict medical supervision, with dosage tailored according to the severity of the condition and patient response. It is essential to monitor for potential adverse effects commonly associated with corticosteroids, including immunosuppression, hyperglycemia, osteoporosis, and adrenal suppression. Abrupt discontinuation should be avoided to prevent withdrawal symptoms and adrenal insufficiency. Patients should be advised on the importance of adherence to prescribed doses and regular follow-up assessments to optimize therapeutic outcomes and minimize risks. Mahacort DZ Suspension is a valuable therapeutic option in the corticosteroid class, offering effective control of inflammatory and autoimmune disorders.